Summary
- Linklaters is advising Fresenius on its full acquisition of the biopharmaceutical company mAbxience.
- This move involves Fresenius acquiring the remaining 45 percent stake in mAbxience.
- The acquisition signifies Fresenius's commitment to expanding its portfolio in the biopharmaceutical sector.
- Legal experts anticipate that this deal could reshape market dynamics in the biopharmaceutical industry.
Join the discussion ā sign up to comment, upvote, and save articles.